I’ve posted on the issue of publishing trial data in industry publications and conferences previously. There is a code of practice that was conceived in conjunction with FDA and the ASX. The conference this week is more of a finance industry event so don’t expect new data from the MAST trial until January 18th oncology conference. This weeks event doesn’t meet the peer review requirement. I will stand corrected if anyone knows more or can interpret the code differently.
IMU Price at posting:
12.0¢ Sentiment: None Disclosure: Held
